ASDS 2024: Galderma presents data on RelabotulinumtoxinA and Sculptra®

Galderma will be showcasing the latest data from its world-leading, science-based aesthetics portfolio at the American Society for Dermatologic Surgery (ASDS) 2024 Annual Meeting, held in Florida from October 17-20. Details on the six abstracts to be presented by Galderma at the ASDS 2024 Annual Meeting can be found below. First author Abstract title Presentation format RelabotulinumtoxinA* K. Beer READY-4: Long-term safety with repeated injections using RelabotulinumtoxinA, a novel liquid formulation botulinum toxin, in the treatment of glabellar and lateral canthal lines E-poster and video H.B. Prather Efficacy and safety of a novel formulation liquid botulinum toxin, RelabotulinumtoxinA, when used for combination treatment of glabellar and lateral canthal lines E-poster and video S.F. Ibrahim RelaBoNT-A treatment of glabellar lines and lateral canthal lines across different ethnicity and race: Pooled data from three phase III studies E-poster and video Sculptra® J. Waibel Bulk RNA-seq analysis of Poly-L-Lactic Acid (PLLA-SCA) vs Calcium Hydroxyapetite (CaHA-R) reveals a novel, adipocyte mediated regenerative mechanism of action unique to PLLA E-poster and video J. Waibel Gene analysis of biostimulators: PLLA-SCA triggers regenerative morphogenesis while CaHA-R induces inflammation upon facial skin injection E-poster and video O. Markowitz A comparative study evaluating the synergistic effects for midface improvement when pairing PLLA-SCA with a skincare regimen Oral presentation “Non-invasive imaging past ultrasound in aesthetic medicine.” 1:30 – 2:30 PM ET October 17 Room: Gatlin A3/A4 All authors are paid consultants or employees of Galderma. *RelabotulinumtoxinA is the first and only ready-to-use liquid neuromodulator created with PEARL™ Technology that is designed to preserve molecule integrity. Galderma completed its European decentralized procedure for RelabotulinumtoxinA (under the brand name of Relfydess™) in July 2024, resulting in a positive decision, and national approvals are now under finalization. RelabotulinumtoxinA also received a marketing authorization in Australia earlier this year. Regulatory applications for RelabotulinumtoxinA for the treatment of frown lines and crow’s feet will continue to be submitted and assessed by additional authorities globally.

The release as fetched from its publisher. galderma.com ↗